top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

122.17 +6.29 (+5.43%)
Streaming Delayed Price Updated: 2:16 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
Discover the top S&P500 movers in Friday's pre-market session. ↗
Via Chartmill
News headline image
2 Reasons to Watch MRK and 1 to Stay Cautious
Merck has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.8%. The stock now trades at $113.99, marking a 20% gain. ... 
Via StockStory
Topics Stocks Supply Chain
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Investors can find much better opportunities. 
Via The Motley Fool
Merck & Co. Inc. (NYSE:MRK): A High Dividend Rating Backed by Strong Profitability and Financial Health ↗
Via Chartmill
Merck (NYSE:MRK) Q1 2026 Results Show Underlying Strength Despite Acquisition-Driven Loss ↗
Via Chartmill
News headline image
1 Dividend ETF Quietly Outperforming the Market Right Now ↗
A lucrative dividend will always attract investors when times are rocky. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
2 Cash-Producing Stocks to Research Further and 1 Facing Challenges
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
Topics Credit Cards
News headline image
2 Dividend Stocks to Double Up On Right Now ↗
They can weather many storms. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy? ↗
Mounjaro generated $8.66 billion in sales in the first quarter. 
Via The Motley Fool
News headline image
The Top 5 Analyst Questions From Merck’s Q1 Earnings Call
Merck’s first quarter results were shaped by robust momentum in its oncology and animal health divisions, as well as meaningful contributions from recent pro... 
Via StockStory
Topics Earnings
News headline image
Tempus AI (TEM) Q1 2026 Earnings Transcript ↗
Tempus AI (TEM) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Monster Dividend Stocks That Could Pay You Through the Next Decade of Chaos ↗
It's time to start thinking at least a little bit defensively by exchanging long-term potential gains for certain near-term cash flow. 
Via The Motley Fool
Topics Artificial Intelligence
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
MRK Q1 Deep Dive: Oncology Strength, New Launches, and Pipeline Milestones Define Quarter
Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q1 CY2026, with sales up 4.9% year on year to $16.29 billion. The co... 
Via StockStory
Top S&P500 movers in Thursday's after hours session ↗
Via Chartmill
News headline image
Merck (MRK) Q1 2026 Earnings Call Transcript ↗
Merck (MRK) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Merck (NYSE:MRK) Surprises With Q1 CY2026 Sales
Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 4.9% year on year to $16.... 
Via StockStory
News headline image
Merck (MRK) Q1 Earnings Report Preview: What To Look For
Global pharmaceutical company Merck (NYSE:MRK) will be reporting results this Thursday before market open. Here’s what investors should know. Merck beat anal... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
Via MarketBeat
Topics Intellectual Property
News headline image
Q4 Earnings Roundup: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Segment
Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Why Merck (MRK) Shares Are Trading Lower Today
What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a... 
Via StockStory
Topics Government Intellectual Property
Which S&P500 stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
3 Reasons We Love Merck (MRK)
Over the past six months, Merck has been a great trade, beating the S&P 500 by 32%. Its stock price has climbed to $118.94, representing a healthy 37.8% incr... 
Via StockStory
Topics Stocks Supply Chain
News headline image
Better Pharma Dividend Stock: Novartis vs. Merck ↗
Both are great stocks to buy in the current environment, but which one is the better bet? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Tech Powerhouse: S&P 500 Eyes 12.6% Growth as AI Revolution Enters Second Gear
As the first-quarter earnings season of 2026 kicks off, Wall Street is bracing for a high-stakes performance that could determine the trajectory of the market for the remainder of the year. With the... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc.... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
1 Momentum Stock on Our Buy List and 2 We Question
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page